IRIS
PERA, MARIA CARMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.237
NA - Nord America 2.577
EU - Europa 1.127
SA - Sud America 757
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 132
OC - Oceania 2
Totale 8.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.443
SG - Singapore 1.361
BR - Brasile 558
VN - Vietnam 490
CN - Cina 438
IT - Italia 426
BD - Bangladesh 356
HK - Hong Kong 278
NL - Olanda 218
FR - Francia 158
ZA - Sudafrica 134
AR - Argentina 75
RU - Federazione Russa 59
DE - Germania 54
IN - India 52
GB - Regno Unito 42
IQ - Iraq 41
CA - Canada 40
AT - Austria 37
CO - Colombia 36
IE - Irlanda 35
MX - Messico 34
EC - Ecuador 26
TR - Turchia 23
PK - Pakistan 22
ID - Indonesia 21
MA - Marocco 20
JP - Giappone 18
VE - Venezuela 18
PH - Filippine 17
PY - Paraguay 15
SA - Arabia Saudita 15
SE - Svezia 15
PL - Polonia 13
UA - Ucraina 13
KR - Corea 12
UY - Uruguay 11
UZ - Uzbekistan 11
JM - Giamaica 10
JO - Giordania 10
KE - Kenya 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
ES - Italia 9
LT - Lituania 9
TH - Thailandia 9
HN - Honduras 8
DZ - Algeria 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
BG - Bulgaria 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
GT - Guatemala 6
IL - Israele 6
NP - Nepal 6
PE - Perù 6
EG - Egitto 5
MY - Malesia 5
AL - Albania 4
KZ - Kazakistan 4
LB - Libano 4
BB - Barbados 3
CH - Svizzera 3
ET - Etiopia 3
GE - Georgia 3
IR - Iran 3
PT - Portogallo 3
RO - Romania 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
CI - Costa d'Avorio 2
EE - Estonia 2
FI - Finlandia 2
GR - Grecia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
RS - Serbia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BZ - Belize 1
Totale 7.885
Salva come PNG Salva come JPEG
Città #
San Jose 632
Singapore 607
Ashburn 311
Council Bluffs 265
Hong Kong 262
Santa Clara 174
Beijing 162
Ho Chi Minh City 152
Dallas 129
Hanoi 125
Johannesburg 120
Groningen 103
Lauterbourg 96
Los Angeles 65
Milan 58
Buffalo 51
New York 50
Boardman 45
São Paulo 44
Moscow 36
Dublin 34
Rio de Janeiro 34
Rome 30
Bologna 27
Nuremberg 25
Phoenix 22
Haiphong 21
Parma 18
Munich 17
Shanghai 17
Naples 16
Chicago 15
Brasília 14
Da Nang 14
Hefei 14
Atlanta 13
Tokyo 13
Vienna 13
Baghdad 12
Quito 12
San Francisco 12
Biên Hòa 11
Amman 10
Brooklyn 10
Turin 10
Ankara 9
Can Tho 9
Columbus 9
Frankfurt am Main 9
Nairobi 9
Ninh Bình 9
Tashkent 9
Toronto 9
Dhaka 8
Guangzhou 8
Hải Dương 8
London 8
Warsaw 8
Bogotá 7
Boston 7
Caracas 7
Curitiba 7
Denver 7
Houston 7
Kingston 7
Modena 7
Montreal 7
New Delhi 7
Philadelphia 7
Tianjin 7
Baku 6
Belo Horizonte 6
Catania 6
Charlotte 6
Dubai 6
Figino 6
Guatemala City 6
Montevideo 6
Recife 6
Seattle 6
Thái Nguyên 6
Amsterdam 5
Aracaju 5
Asunción 5
Bangkok 5
Brescia 5
Buenos Aires 5
Carpi 5
Casablanca 5
Erbil 5
Forlì 5
Genoa 5
Guarulhos 5
Hyderabad 5
Istanbul 5
Jeddah 5
Karachi 5
Karbala 5
Medellín 5
Mexico City 5
Totale 4.278
Salva come PNG Salva come JPEG
Nome #
Airway Colonization in Children with Medical Complexity: Challenges and Management Strategies 168
Beyond Muscle Weakness: Unraveling Endocrine and Metabolic Dysfunctions in Duchenne Muscular Dystrophy, a Narrative Review 149
Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence 116
An observational study of functional abilities in infants, children, and adults with type 1 SMA 102
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 99
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression 99
Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review 97
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 96
Spinal muscular atrophy — insights and challenges in the treatment era 95
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 95
What did we learn from new treatments in SMA? A narrative review 94
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 94
Risdiplam in Type 1 Spinal Muscular Atrophy 93
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 87
Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital myopathy 86
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 85
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 84
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 84
Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 84
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 83
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 82
An observational study of functional abilities in infants, children, and adults with type 1 SMA 82
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 81
Early neurodevelopmental assessment in Duchenne muscular dystrophy 81
Clinical Variability in Spinal Muscular Atrophy Type III 79
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 78
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 77
Assessing floppy infants: a new module 76
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 76
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 76
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 76
Design and Usability Testing of a Novel Internet-Delivered Cognitive Behavioral Therapy (iCBT) Software Platform for Children with Anxiety 75
Developmental milestones in type I spinal muscular atrophy 75
Longitudinal natural history of type I spinal muscular atrophy: A critical review 75
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 74
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 74
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 73
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 72
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 72
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 71
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 71
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 71
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 71
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded 71
Italian validation of the SMA independence scale–upper limb module 70
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 70
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 70
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 70
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 70
Sleep disorders in spinal muscular atrophy 69
Early treatment of type II SMA slows rate of progression of scoliosis 69
Traumatic Childbirth Experiences and their Association with Postpartum Psychiatric Disorders: A Systematic Review 69
Revised upper limb module for spinal muscular atrophy: Development of a new module 68
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 68
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 67
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 67
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 67
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 66
Old measures and new scores in spinal muscular atrophy patients 66
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 66
Development of an academic disease registry for spinal muscular atrophy 65
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 65
Developmental milestones in type I spinal muscular atrophy 65
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 64
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 64
Neonatal hypotonia and neuromuscular conditions 63
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 63
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 62
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 62
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 62
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 62
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 62
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 62
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 62
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 61
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 61
How to Manage Electrical Status Epilepticus in Sleep 61
Long term follow-up of scoliosis progression in type II SMA patients 61
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 61
Gain and loss of abilities in type II SMA: A 12-month natural history study 60
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 59
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 59
Revised upper limb module for spinal muscular atrophy: 12 month changes 58
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 58
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 58
Predominant distal muscle involvement in spinal muscular atrophy 57
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 57
Revised upper limb module for spinal muscular atrophy: Development of a new module 56
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 56
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 56
Treatment of spinal muscular atrophy 56
Sudden and isolated Broca's aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children 55
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 55
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 55
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 55
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 54
MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients 54
Antiviral Treatment for Congenital Cytomegalovirus Infection in Extremely Preterm Newborn: A Case Report and Literature Review 54
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 54
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 53
Totale 7.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.874
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.631 0 0 318 55 85 97 50 55 234 215 111 411
2025/20265.193 325 491 635 479 585 202 552 120 564 451 470 319
2026/20271.205 263 265 421 256 0 0 0 0 0 0 0 0
Totale 8.029